Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae

1It is well known that Klebsiella pneumoniae is ubiquitous in nature, one of the most relevant opportunistic pathogens, and causes various human infections such as bloodstream infection (BSI), urinary tract infection (UTI), surgical-site infection, and pneumonia. Resistance can develop in K. pneumoniae isolates, notably producing extended-spectrum β-lactamases (ESBLs). ESBL-producing strains of K. pneumoniae are currently found throughout the world and have caused numerous outbreaks of infection. Carbapenems represent the first-line therapy for severe infection by ESBL-producing K. pneumoniae. However, since Yigit et al. reported the first K. pneumoniae carbapenem (KPC)-producing K. pneumoniae isolate in North Carolina in 1996, carbapenem-resistant strains have increased rapidly, rising from 1.6 to 10.4% associated with central line blood-stream infections between 2001 and 2011 in the United States, and have aroused widespread attention, presenting a challenge because the antimicrobial treatment options remain very restricted.

2Carbapenem-resistant K. pneumoniae (CRKP) deactivates the carbapenems through two main mechanisms: (1) acquisition of carbapenemase genes that encode for enzymes capable of hydrolyzing carbapenems—the three most important carbapenemase types being KPC-type enzymes, metallo-β-lactamases (VIM, IMP, NDM), and OXA-48 type enzymes; and (2) reduction in the accumulation of antibiotics by a quantitative and/or qualitative deficiency of porin expression in combination with overexpression of β-lactamases that possess weak affinity for carbapenems.

3Most researchers reported higher mortality rates among persons infected with CRKP isolates while others reported contrary results. In recent years, many studies from single medical centers or individual countries have reported mortality rates in patients infected with CRKP, but until now there has been no systematic review focusing on mortality resulting from carbapenem-resistant infections in general. Although in a recent meta-analysis Falagas et al. reported a higher all-cause mortality among patients infected with carbapenem-resistant Enterobacteriaceae than in those with carbapenem-susceptible infections, but their research included only nine studies. Considering this scenario, we conducted a systematic review and meta-analysis to estimate the mortality of patients infected with CRKP, and analyzed mortality resulting from multiple infection types and patients conditions.

4Two independent examiners (LF.X. and XX.S.) searched entries in the PubMed and EMBASE databases from their inception until December 22, 2015 to identify potentially relevant studies. The search terms included “Klebsiella pneumoniae” AND resistance AND (“carbapenem” OR “imipenem” OR “meropenem” OR “ertapenem”). The language was restricted to English.

5Studies were considered in accordance with inclusion criteria if articles reported mortality of patients infected with CRKP. Research that focused on children, did not differentiate mortality between infection and colonization, did not define the strains that were carbapenem resistant, and did not present the exact death toll were excluded. In this analysis, carbapenem resistance was defined as resistance to carbapenems such as imipenem, meropenem, and ertapenem, irrespective of susceptibility to other antibiotics.

6The articles were assessed for quality of the cohort or case–control studies included in the systematic analysis according to the Newcastle-Ottawa scale (NOS) score, ranging from 0 to 9. Studies with a NOS score of 5 or greater were included in this analysis.

7Two independent investigators (LF.X. and XX.S.) extracted information from eligible articles. Divergences were solved by discussion and consultation of the relevant literature. The information extracted from original publications included title, first author, year of publication and experiment, type of study, sample size, characteristics of the study population (mean age, sex, type of infection, mean severity of underlying disease), and crude mortality rates in patients infected with CRKP and carbapenem-susceptible K. pneumoniae (CSKP). If articles reported mortality from both infection and colonization, we extracted information only regarding infections.

8We calculated the pooled odds ratio (OR) and 95% confidence interval (CI) by comparing crude mortality in patients with CRKP with that in patients with CSKP. Between-study heterogeneity was assessed by the χ2 test (p < 0.10 was selected to indicate the presence of heterogeneity, in which case a random-effects model was adopted; otherwise a fixed-effects model was applied) and I 2 test (to assess the degree of heterogeneity). We then calculated pooled rates of mortality in patients infected with CRKP, and stratified analyses with respect to geographic location, infection types, carbapenemase types, and patients conditions performed. Freeman–Tukey arcsine transformations were used to stabilize the variances, and after the meta-analysis we transformed the summary estimates and the CI boundaries back to proportions using the sine function. We used Stata version 12.0 software for all statistical calculations.

9We identified and screened 3168 articles. After exclusion by title and abstract, the remaining 87 articles were subjected to full-text assessment for eligibility. Among these articles, 12 were duplicates, seven did not differentiate between infection- and colonization-related mortality, and six did not report valid data. Ultimately, 62 studies were analyzed based on the inclusion and exclusion criteria (Fig. 1).

10The basic characteristics of these 62 studies are summarized in Table 1. These articles were published from 1999 to 2015 and the sample size varied across studies, ranging from 7 to 1022. The total number of patients in this systematic review was 4701, of whom 2462 had CRKP infection and the remainder CSKP infection. Among these patients, the reported death was 1018 among the CRKP patients and 398 among the CSKP patients. In the pooled analysis, the overall mortality was 42.14% (95% CI 37.06–47.31) in patients infected with CRKP and 21.16% (95% CI 16.07–26.79) in CSKP patients (Table 2).

11Among the included articles, 22 compared mortality between patients infected with CRKP and CSKP. The summary estimate of these studies from the random-effects model suggested that patients with CRKP had a significantly higher mortality than those with CSKP in the univariate analysis (pooled crude OR 2.80; 95% CI 2.15–3.65) with a moderate heterogeneity I 2 of 33.9% (p = 0.031) (Fig. 2).

12As shown in Table 2, 722 patients had BSI and 284 had UTI, 479 were in an intensive care unit (ICU), and 362 underwent solid organ transplantation (SOT). In the pooled analysis, the mortality was 54.30% (95% CI 47.51–61.02), 13.52% (95% CI 7.50–20.92), 48.9% (95% CI 44.47–53.46), and 43.13% (95% CI 32.40–54.16) in BSI, UTI, ICU-admission, and SOT patients, respectively.

13In this subgroup analysis, we mainly analyzed the mortality of patients infected with KPC-producing K. pneumoniae and VIM-producing K. pneumoniae. In the articles included, 302 patients were infected with KPC-producing K. pneumoniae and 73 were infected with VIM-producing K. pneumoniae. The mortality among these two types of carbapenemases was 47.66% (95% CI 38.61–56.79) and 46.71% (95% CI 35.81–57.73), respectively (Table 2).

14Twenty-three studies were carried out in North America, eight in South America, twenty-one in Europe, and ten in Asia. The rate of mortality was 33.24% (95% CI 25.08–42.00) of 980 patients in North America, 46.71% (95% CI 39.83–53.66) of 191 in South America, 50.06% (95% CI 41.45–58.62) of 860 in Europe, and 44.82% (95% CI 37.83–51.91) of 431 in Asia (Table 2).

15ESBL-producing K. pneumoniae as an opportunistic pathogen is becoming more challenging to treat because of the emergence of carbapenem resistance, and has a significant influence on patient mortality. The primary result of this analysis was the pooled crude mortality of 42.14% among patients with CRKP, which is intimately connected with patients’ health and physical status.

16Although it is accepted that drug resistance is associated with increased mortality because patients tend to receive inappropriate empiric therapy in general, other studies have found no such relationship. Bhavnani et al. reported that clinical success was similar between patients with ESBL and those with non-ESBL-producing K. pneumoniae, and ESBL production alone did not appear to be an independent risk factor for treatment failure. Kim et al. also found that ESBL production was not significantly associated with death. In addition, García-Sureda et al. reported that CRKP isolates are less virulent and fit than CSKP isolates in an antibiotic-free environment. We conducted this systematic review and meta-analysis to estimate the mortality of patients infected with CRKP in general and to study the factors related to mortality resulting from this infection. We found that patients infected with CRKP had significantly higher mortality in comparison with CSKP (crude OR 2.80). To identify risk factors associated with the higher mortality of CRKP infections, we conducted a stratified analysis of patient condition, carbapenemase types, and study location.

17Based on multiple patient conditions, our analysis confirmed that patients with CRKP in association with BSI, ICU admission, or SOT have a higher mortality than the pooled mortality, although UTI patients have a lower mortality than the pooled overall mortality, even lower than that of CSKP patients. From this result, we assumed that patient survival has a close relationship with patients’ underlying illness and comorbidities. Mouloudi et al. reported that BSI, ICU admission, and recent receipt of a SOT were associated with ICU and in-hospital mortality in patients infected with CRKP. In addition, patients who had undergone organ transplantation or ICU admission were always subjected to surgical procedures, prolonged ICU stay, preexisting immunosuppression, and the use of invasive devices, which contributed to patients’ poor physical condition and resultant higher mortality. In contrast, Daikos et al. suggested that UTI is a relatively mild infection that has only a slight influence on the general condition of patients, and carries a low mortality in general. It has been shown that factors such as underlying illness and comorbidities have a more important influence on mortality than appropriate empiric treatment with multidrug-resistant Gram-negative bacteria. Although the underlying patient’s condition is important for the outcome of such patients, meanwhile a timely effective treatment can also help to improve the survival rate. Patients in a poor state of health with CRKP were subjected to pathogens longer compared to CSKP infection due to lack of an effective therapy, ultimately, led to a higher mortality.

18In the present analysis, patients infected with KPC-producing K. pneumoniae have a higher mortality than pooled overall mortality (47.66 vs 42.14%). This result may contribute to KPC-producing K. pneumoniae having stronger invasiveness, and the KPC-encoding blaKPC always carry other drug-resistant genes, leading to a pronounced drug resistant. Previous studies have demonstrated K. pneumoniae-encoding blaKPC to be an independent risk factor in patient mortality. In addition, KPC-producing K. pneumoniae is considered a successful pathogen because of its ability to persist and spread, causing nosocomial outbreaks. Bratu et al. reported that KPC-producing K. pneumoniae isolates are resistant to not only all β-lactam antimicrobials but also frequently other classes of antimicrobials, such as aminoglycosides and fluoroquinolones. In this systematic review, the patients from North America have lower mortality in comparison with the other three locations. This phenomenon may be attributed to a higher level of medical care and different treatment methods in North America, such as combination antibiotics, treatment with polymyxins and tigecycline, and adjunctive procedures (e.g., catheter removal, drainage, or debridement). There is evidence that tigecycline and polymyxins have activity against many CRKP isolates in vitro, and there have been cases reported of successful treatment of CRKP infection with polymyxins and tigecycline. Patel et al. also reported that removal of the focus of infection (i.e., debridement) was independently associated with patient survival.

19There are several limitations to this analysis. First, as the included studies reported only unadjusted data on mortality, we analyzed only crude mortality among patients with CRKP. Second, most studies may have lacked power in differentiating death caused by CRKP from any other factors, and it is difficult to draw definitive conclusions from current evidence because of the residual confounding factors and small sample sizes in many studies. Third, some studies included in our meta-analysis did not define a cutoff value to judge the susceptibility of K. pneumoniae to carbapenems, and when defined the cutoff value varied among studies owing to different reference criteria. Thus, there exists the potential for heterogeneity. Fourth, most studies were retrospective in nature and thus susceptible to selection bias. Last, we selected only English-language articles, thus limiting the scope of our analysis.

20Our study suggests that patients infected with CRKP have a higher mortality than those infected with CSKP, especially patients with BSI, ICU admission, or SOT intervention. We suggest that the survival of patients has a close relationship with their physical condition. Thus, our results imply that attention should be paid to CRKP infection in patients in a poor state of health, and that strict infection control measures and new antibiotics are required to protect against CRKP infection.